{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:54:55Z","timestamp":1740142495413,"version":"3.37.3"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regeneron"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.iac.2018.12.009","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T23:34:14Z","timestamp":1554334454000},"page":"221-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Personalized Medicine and Pediatric Asthma"],"prefix":"10.1016","volume":"39","author":[{"given":"Nathan M.","family":"Pajor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa W.","family":"Guilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iac.2018.12.009_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MOP.0000000000000361","article-title":"Moving towards precision care for childhood asthma","volume":"28","author":"Mokhallati","year":"2016","journal-title":"Curr Opin Pediatr"},{"issue":"3","key":"10.1016\/j.iac.2018.12.009_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MOP.0b013e32835357ab","article-title":"Pediatric asthma phenotypes","volume":"24","author":"Cowan","year":"2012","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.iac.2018.12.009_bib3","unstructured":"From the global strategy for asthma management and prevention. Global initiative for asthma (GINA). 2018."},{"issue":"5 Suppl","key":"10.1016\/j.iac.2018.12.009_bib4","first-page":"S94","article-title":"Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma\u2014summary report 2007","volume":"120","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2018.12.009_bib5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-4496","article-title":"Preventing exacerbations in preschoolers with recurrent wheeze: a meta-analysis","volume":"137","author":"Kaiser","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ACI.0000000000000344","article-title":"Management of preschool recurrent wheezing and asthma: a phenotype-based approach","volume":"17","author":"Beigelman","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.12.009_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaci.2008.12.1120","article-title":"Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma","volume":"123","author":"Bacharier","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2018.12.009_bib8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jaci.2016.09.028","article-title":"Individualized therapy for persistent asthma in young children","volume":"138","author":"Fitzpatrick","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.iac.2018.12.009_bib9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ppul.23429","article-title":"Efficacy of oral corticosteroids in the treatment of acute wheezing episodes in asthmatic preschoolers: systematic review with meta-analysis","volume":"51","author":"Castro-Rodriguez","year":"2016","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.iac.2018.12.009_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaip.2015.10.017","article-title":"Should a preschool child with acute episodic wheeze be treated with oral corticosteroids? A Pro\/Con debate","volume":"4","author":"Beigelman","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.iac.2018.12.009_bib11","article-title":"Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children","author":"Brodlie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.iac.2018.12.009_bib12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2213-2600(14)70186-9","article-title":"Intermittent montelukast in children aged 10\u00a0months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial","volume":"2","author":"Nwokoro","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.iac.2018.12.009_bib13","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jaci.2014.10.001","article-title":"Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis","volume":"135","author":"Beigelman","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2018.12.009_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1465-9921-11-90","article-title":"Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis","volume":"11","author":"Beigelman","year":"2010","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.iac.2018.12.009_bib15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaci.2016.03.054","article-title":"Azithromycin therapy during respiratory syncytial virus bronchiolitis: upper airway microbiome alterations and subsequent recurrent wheeze","volume":"138","author":"Zhou","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.iac.2018.12.009_bib16","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1001\/jama.2015.13896","article-title":"Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial","volume":"314","author":"Bacharier","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.iac.2018.12.009_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-2600(15)00500-7","article-title":"Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Stokholm","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.iac.2018.12.009_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2006.09.042","article-title":"Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial","volume":"119","author":"Sorkness","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2008.11.016","article-title":"Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma","volume":"123","author":"Knuffman","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2004.11.014","article-title":"Characterization of within-subject responses to fluticasone and montelukast in childhood asthma","volume":"115","author":"Szefler","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.12.009_bib21","article-title":"Early emergency department treatment of acute asthma with systemic corticosteroids","author":"Rowe","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.iac.2018.12.009_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002308","article-title":"Early use of inhaled corticosteroids in the emergency department treatment of acute asthma","author":"Edmonds","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.iac.2018.12.009_bib23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1067\/mai.2003.1391","article-title":"Response to montelukast among subgroups of children aged 2 to 14 years with asthma","volume":"111","author":"Meyer","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2018.12.009_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa1001278","article-title":"Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids","volume":"362","author":"Lemanske","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jaci.2014.03.039","article-title":"Eczema and race as combined determinants for differential response to step-up asthma therapy","volume":"134","author":"Malka","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.iac.2018.12.009_bib26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1056\/NEJMoa1511049","article-title":"Serious asthma events with fluticasone plus salmeterol versus fluticasone alone","volume":"374","author":"Stempel","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iac.2018.12.009_bib27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMoa1606356","article-title":"Safety of adding salmeterol to fluticasone propionate in children with asthma","volume":"375","author":"Stempel","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iac.2018.12.009_bib28","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJMoa1511190","article-title":"Serious asthma events with budesonide plus formoterol vs. budesonide alone","volume":"375","author":"Peters","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaci.2016.01.011","article-title":"Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial","volume":"138","author":"Hamelmann","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.12.009_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.anai.2015.06.029","article-title":"Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis","volume":"115","author":"Rodrigo","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.12.009_bib31","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaci.2013.08.003","article-title":"Predictors of response to tiotropium versus salmeterol in asthmatic adults","volume":"132","author":"Peters","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.12.009_bib32","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaip.2018.02.006","article-title":"The tempest: difficult to control asthma in adolescence","volume":"6","author":"Burg","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"author":"Omalizumab FDA Label","key":"10.1016\/j.iac.2018.12.009_bib33"},{"issue":"5","key":"10.1016\/j.iac.2018.12.009_bib34","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1542\/peds.110.5.e55","article-title":"Omalizumab improves asthma-related quality of life in children with allergic asthma","volume":"110","author":"Lemanske","year":"2002","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib35","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.iac.2018.12.009_bib36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.iac.2018.12.009_bib37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.iac.2018.12.009_bib38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1016\/j.iac.2018.12.009_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.iac.2018.12.009_bib40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2018.12.009_bib41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/archdischild-2011-301570","article-title":"The oral corticosteroid-sparing effect of omalizumab in children with severe asthma","volume":"97","author":"Brodlie","year":"2012","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.iac.2018.12.009_bib42","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.12.009_bib43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaip.2014.06.022","article-title":"Severe asthma in children","volume":"2","author":"Guilbert","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.iac.2018.12.009_bib44","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaip.2013.01.011","article-title":"Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents","volume":"1","author":"Sorkness","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"13","key":"10.1016\/j.iac.2018.12.009_bib48","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"author":"Mepolizumab FDA Label","key":"10.1016\/j.iac.2018.12.009_bib49"},{"issue":"13","key":"10.1016\/j.iac.2018.12.009_bib50","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9842","key":"10.1016\/j.iac.2018.12.009_bib51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.iac.2018.12.009_bib52","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iac.2018.12.009_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"author":"Benralizumab FDA Label","key":"10.1016\/j.iac.2018.12.009_bib54"},{"issue":"9","key":"10.1016\/j.iac.2018.12.009_bib55","article-title":"Macrolides for chronic asthma","author":"Kew","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"10095","key":"10.1016\/j.iac.2018.12.009_bib56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.iac.2018.12.009_bib57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.anai.2017.09.058","article-title":"Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma","volume":"119","author":"Blaiss","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","article-title":"Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial","volume":"181","author":"Castro","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.iac.2018.12.009_bib59","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2013.08.009","article-title":"Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma","volume":"132","author":"Wechsler","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5S","key":"10.1016\/j.iac.2018.12.009_bib60","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaip.2017.07.008","article-title":"New and anticipated therapies for severe asthma","volume":"5","author":"Peters","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.iac.2018.12.009_bib61","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/ppul.24075","article-title":"Can inflammatory markers in induced sputum be used to detect phenotypes and endotypes of pediatric severe therapy-resistant asthma?","volume":"53","author":"Eller","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.iac.2018.12.009_bib62","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/thoraxjnl-2018-211540","article-title":"Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis","volume":"73","author":"Petsky","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.iac.2018.12.009_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaip.2015.10.008","article-title":"Severe asthma in children: lessons learned and future directions","volume":"4","author":"Fitzpatrick","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2018.12.009_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40413-017-0169-9","article-title":"Psychological and lifestyle risk factors for asthma exacerbations and morbidity in children","volume":"10","author":"Oland","year":"2017","journal-title":"World Allergy Organ J"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaip.2016.09.019","article-title":"Self-reported stressful life events during adolescence and subsequent asthma: a longitudinal study","volume":"5","author":"Oren","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2018.12.009_bib66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/02770903.2013.794236","article-title":"Interactive support interventions for caregivers of asthmatic children","volume":"50","author":"Chen","year":"2013","journal-title":"J\u00a0Asthma"},{"issue":"6","key":"10.1016\/j.iac.2018.12.009_bib67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jpepsy\/jss123","article-title":"Efficacy of a parent-youth teamwork intervention to promote adherence in pediatric asthma","volume":"38","author":"Duncan","year":"2013","journal-title":"J\u00a0Pediatr Psychol"},{"issue":"2","key":"10.1016\/j.iac.2018.12.009_bib68","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/02770903.2011.554941","article-title":"Preliminary evidence for the feasibility of a stress management intervention for 7- to 12-year-olds with asthma","volume":"48","author":"Long","year":"2011","journal-title":"J\u00a0Asthma"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118301139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118301139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T02:42:43Z","timestamp":1565145763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856118301139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0889856118301139"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2018.12.009","relation":{},"ISSN":["0889-8561"],"issn-type":[{"type":"print","value":"0889-8561"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized Medicine and Pediatric Asthma","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2018.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}